Due to the exquisite specificity and potency of the immune system, vaccination is in theory the most precise and powerful approach for controlling cancer. However, current data from clinical trials indicate that vaccination rarely yields significant benefits for cancer patients in terms of 
Introduction
The establishment of tumor-reactive CD8 + CTLs by vaccination represents a potentially effective route for the management of cancer. CTLs have unequivocal specificity and potency to destroy transformed cells throughout the body without inflicting significant damage to normal tissue (1, 2) . Generation of immune memory after tumor eradication should also protect against long-term relapse (3, 4) . These advantages of vaccination over conventional cancer treatments fueled much of the enthusiasm for vaccination in the early 21 st century (5, 6) . However, this enthusiasm has gradually waned due to poor clinical outcomes, even after aggressive vaccination regimens (7) (8) (9) (10) .
These results from early clinical trials persuaded investigators to elucidate mechanisms responsible for the failure of vaccination. Multiple strategies are being studied to overcome hurdles of the immunosuppressive tumor milieu (11) . However, tumor cells themselves may adapt to selection pressures imposed by vaccination, making them impervious to immune surveillance. Here we show that vaccination induces tumor cells to express Nanog, a homeobox transcription factor pivotal in self-renewal of embryonic stem cells. Nanog confers tumor cells with an immune-resistant and stem-like phenotype, thereby facilitating tumor progression.
Knockdown of Nanog expression with small interfering RNA (siRNA) renders the tumor vulnerable to immune attack and leads to reduction in tumor growth. We also show that Nanog is present in some human cancer cells and that it promotes immune escape and stem-like features in this setting. Our data suggest that Nanog-dependent evolution of tumor cells towards an immuneresistant and stem-like phenotype poses a critical, previously unrecognized obstacle to vaccination. Inhibition of Nanog provides an avenue to overcome this obstacle and may help realize the clinical promise of cancer vaccination. chitosan nanoparticles were prepared as previously described (12) .
Research. selection (0.5μg/ml), the transduced cells were cultured with 0.25 μg/ml of puromycine. Tumor sphere-forming assays. Cells were plated at 5×10 3 cells per well in ultra low attachment vessels (Corning, MA) containing serum-free DMEM/F12 (Thermo Scientific, MA), supplemented with epidermal growth factor (20 ng/ml), basic fibroblast growth factor (10 ng/ml), and B27 (Invitrogen). Medium was replaced every 3 days to replenish growth factors and nutrients. Real-time quantitative RT-PCR. Total RNA from TC-1 cells was purified using TRIzol reagent (Invitrogen). First-strand synthesis and real-time PCR were performed to detect mNanog with TaqMan Universal SYBR Green Master Mix (Roche, IN) using the primer set: 5' -ATGAGTGTGGATCCAGCTTG -3' (forward), 5' -TCACACGTCTTGAGGTTG -3' (reverse).
Immunofluorescence microscopy. TC-1 cells were fixed in 4% paraformaldehyde for 10 minutes. After washing with PBS, cells were treated with 0.2% Triton X-100 and blocked for 1 hour in 1% BSA solution. Primary antibodies against Nanog or Oct4 (Santa Cruz Biotechnology, CA) were added for overnight incubation in a humidified chamber at 4°C. Cells were stained with Alexa Flour 488-labeled goat anti-mouse IgG and DAPI. Expression of Nanog and Oct4 was analyzed by confocal laser scanning microscopy (Carl Zeiss, Oberkochen, Germany) as previously described (14) .
Western blot. A total of 5×10 5 cells was used to perform Western blot as previously described (15) . Primary antibodies against CDK2, cyclin E, cyclin A (Cell Signaling Technology, MA), Nanog, Oct4, Sox2, c-Myc, p21, and p27 (Santa Cruz Biotechnology), Nestin (BD Biosciences, CA), ALDH3A1, and Musanshi1 (Abcam, CA) were used at 1:1000 dilution. Immune-reactive bands were visualized by enhanced chemiluminescence (Elpis Biotech, Daejeon, Korea). hours. Surface staining for CD8 and intracellular staining for IFN-γ followed by flow cytometry were performed as previously described (16 
Results
Vaccination enhances growth and stem-like properties of tumor cells. According to the cancer immunoediting theory, heterogeneous tumor cells are continuously subjected to host immune surveillance (17, 18) . Cells vulnerable to immune surveillance are eliminated, while cells that evade detection and killing proliferate. A corollary of this theory is that vaccination should accelerate and intensify the selection of these escape variants. We previously devised a system-coined here as vaccination-induced cancer evolution (VICE)-to simulate immunoediting in the context of vaccination (19) . We applied VICE to generate immuneresistant tumor cells in a human papillomavirus (HPV) type-16-associated cervical cancer model, TC-1, which allows us to accurately trace tumor-reactive CTLs based on specificity for the HPV antigen E7 (13) . After 3 serial passages, we created TC-1 P3, a derivative of the parental TC-1 line (P0), that is completely impervious to Sig/E7/LAMP-1-based vaccination (19) (20) (21) . and decreased cyclin-dependent kinase inhibitor p21 expression ( Figure 1C ). These data show that P3 cells have greater proliferative capacity than P0 cells. We next explored the stem-like properties of P3 cells. CSCs tend to form spheres when cultured in low-attachment vessels under serum-depleted conditions. In these conditions, P3 cells produced more spheres than P0 cells ( Figure 1D ), and these spheres could be continuously passaged ( Figure 1E ). P3 cells also had increased expression of stemness markers CD133, CD44, and aldehyde dehydrogenase (ALDH) (Supplemental Figure 1A) . CSCs can also give rise to tumors in immunocompromised mice.
We inoculated NOD/SCID mice with 10 Vaccination induces Nanog expression in tumor cells. Since the TC-1 P3 line had elevated levels of cells with stem-like properties, we assessed the expression of molecules associated with stemness in the P3 and P0 lines. Of the candidate molecules, only Nanog-a transcription factor pivotal in self-renewal of embryonic stem cells-showed differential expression in P3 compared to P0 cells. Nanog was upregulated nearly 10-fold in the P3 cells (Figure 2A ) and was detectable in 70% of the P3 cells compared to 10% of the P0 cells ( Figure 2B ). To test if the induction of Nanog in the P3 line could be independent of vaccination, we applied VICE and measured Nanog mRNA levels by real-time PCR at the P0, P1, P2, and P3 stages. As a control, we performed the same analysis in N1, N2, and N3 cells generated from mice implanted with TC-1 without vaccination. Nanog mRNA levels were virtually identical in the P0, N1, N2, and N3 stages. By contrast, Nanog mRNA levels gradually increased from the P0 to the P3 stages, resulting in almost 10 times more Nanog mRNA in P3 cells than in P0 cells ( Figure 3A) . The frequency of cells positive for Nanog protein also increased from the P0 (15%) to P3 (80%) stages but remained at 15% in the N1 to N3 stages (Figure 3B, C) . Thus, accumulation of Nanog in tumor cells is a direct consequence of vaccination. To show that Nanog directly promotes the enrichment of tumor cells with a stem-like phenotype, we retrovirally-transduced TC-1 P0 cells with DNA encoding Nanog (P0/Nanog) or empty vector (P0/no insert) and characterized their growth and stem-like features. As expected, the results from these experiments were the inverse of those from the siRNA experiments.
Compared to P0/no insert cells, P0/Nanog cells divided more rapidly (Figure 4D (Figure 5C, H) . These data suggest that the resistance of P3 cells to adaptive immune surveillance is not due to changes in antigen-presentation but an intrinsic immune resistance to CTL-mediated killing. To investigate this, we treated P3 cells with either siGFP or siNanog and then mixed them with E7-specific CTLs or GrB to cause apoptosis.
We measured the frequency of cells positive for the active form of caspase-3 as an index of apoptosis. After adding GrB, only 6% of siGFP-treated P3 cells underwent apoptosis, but the number increased to 60% in siNanog-treated cells (Figure 5D ). Similarly, a larger degree of apoptosis was seen in siNanog-treated P3 cells mixed with E7-specific CTLs relative to siGFPtreated P3 cells mixed with E7-specific CTLs ( Figure 5E ). We also found significantly less We tested whether this is also the case in vivo by challenging mice with TC-1 P0/Nanog or P0/no insert cells followed by adoptive transfer of E7-specific CTLs or isotonic saline control.
Tumor size was nearly identical in mice implanted with P0/Nanog cells regardless of whether they received adoptive therapy, indicating that the P0/Nanog cells were impervious to killing by CTLs ( Figure 5K) . Importantly, tumor size was similar in mice implanted with P0/Nanog cells and P0/no insert cells without adoptive therapy, demonstrating that Nanog contributes to tumorigenicity by rendering tumor cells insusceptible to immune surveillance rather than through boosting their intrinsic proliferative capacity ( Figure 5K) . However, tumors consistently failed to grow in mice implanted with P0/no insert cells and then subjected to adoptive therapy ( Figure   5K ). These findings show that Nanog expression is responsible for both the stem-like and immune-resistant phenotype acquired by tumor cells after vaccination.
Inhibition of Nanog leads to tumor control by the adaptive immune system. Because we established Nanog's central role in enhancing the tumor stem-like and immune-resistant phenotype after vaccination, we reasoned that inhibition of Nanog could control tumor progression. We challenged mice with TC-1 P3 cells. After the tumor formed, the mice received systemic injections of nanoparticles carrying siGFP or siNanog followed by adoptive transfer of CFSE-labeled, E7-specific CTLs or isotonic saline control ( Figure 6A) . Delivery of siNanog strongly retarded tumor growth, and the tumor was virtually eradicated in mice given siNanog and E7-specific CTLs (Figure 6B ). Mice administered siGFP had rapid tumor growth, regardless of whether they received adoptive therapy ( Figure 6B) . 15 days after the tumor challenge, siNanog-treated mice had tumors less than one tenth the size of tumors in siGFP-treated mice.
Adoptive therapy further reduced the tumor size to one half in the siNanog-treated mice ( Figure   6C ). We harvested the tumors and characterized the proliferative and survival features of their component cells. siNanog-treated mice had lower levels of cyclin A and higher levels of p21 within the tumor compared to siGFP-treated mice ( Figure 6D) . Furthermore, only 60% of tumor cells in siNanog-treated mice were positive for Ki67, a marker of proliferation ( Figure 6E ). By contrast, nearly 100% of tumor cells in siGFP-treated mice were Ki67 + ( Figure 6E) . 25% of tumor cells in siNanog-treated mice with adoptive therapy underwent apoptosis; however, the frequency was only 5% in siNanog-treated mice without adoptive therapy or in siGFP-treated mice (with or without adoptive therapy) ( Figure 6G ). There was no difference in the amount tumor-infiltrating transferred CTLs between siNanog-and siGFP-treated mice ( Figure 6F ).
These results demonstrate that inhibiting Nanog restores tumor susceptibility to immunological control even after immune selection by vaccination. Interestingly, we also noted that the frequency of CD133 + cells in the TC-1 P3 tumor was dropped from 64% to 36% after delivery of siNanog, indicating that Nanog inhibition impairs the enhancement of the stem-like phenotype (Supplemental Figure 1C) . Nanog confers stem-like and immune-resistant properties to human cancer cells. We also examined the presence of Nanog in human cervical cancers. Nanog was highly expressed in cells pulsed with E7 49-57 were 6 times more resistant to GrB-or E7-specific CTL-mediated apoptosis, respectively, compared to empty vector-transduced cells (Figure 7C, D) . Thus, the presence of Nanog represents an important feature of some human cancers, promoting the gain of a stem-like and immune-resistant phenotype.
Discussion
We previously developed VICE, a system that selects for tumor immune escape variants (P3) after vaccination in a cervical cancer model (19) . We found that these P3 cells impervious to lysis by tumor-reactive CTLs proliferated more rapidly in culture than the parental P0 cells from which they were derived and exhibited various hallmarks of CSCs, including sphereforming capacity, tumor-initiating properties, and expression of pluripotency markers, including CD133, CD44, and ALDH. It is unclear whether the P3 cells are definitively CSCs. However, since the P3 cells were more pronounced in all of the above features compared to the P0 population, we conclude that P3 has been polarized towards a stem-like phenotype. Thus, in addition to chemotherapy or radiotherapy, vaccination can select for tumor cells with phenotypes resembling CSCs (27-30).
Research. We also found that, consistent with the cancer immunoediting theory, vaccination selects for tumor cells with an immune-resistant phenotype. This phenotype could arise from either increased proliferation or survival of tumor cells (18) triggered by Nanog. Our data suggest that the immune-resistant phenotype is not likely due to a faster growth rate of the TC-1/Nanog tumor compared to the TC-1/no insert tumor because we did not observe a significant difference in tumor progression after challenge with TC-1/Nanog or TC-1/no insert in the absence of adoptive transfer of E7-specific CD8+ CTLs (Figure 5K) . It is more likely that Nanog confers an intrinsic protection from CTL-mediated killing since mice injected with TC-1/no insert, but not TC-1/Nanog, showed reduced tumor growth rates with adoptive transfer of E7-specific CTLs.
This conclusion is supported by the observation that Nanog-expressing cells are impervious to CTL-mediated killing but still have similar growth rates as TC-1/no insert cells (Supplemental
Figure 2).
One important concern is whether increased Nanog expression is driven in an antigenspecific manner or by inflammatory responses to vaccination. Our data indicate that Nanog expression leads to protection from antigen-specific CTL-mediated killing, resulting in the selective survival and proliferation of Nanog-expressing cells in the tumor (Figures 5E, 5J, 7D, and Supplemental Figure 2) . Furthermore, in vivo immune selection of Nanog-expressing tumor cells was demonstrated after adoptive transfer of E7-specific CTLs (Figure 5K) . Therefore, our data suggest that Nanog expression is primarily driven by immune selection mediated by antigen-specific CTLs. However, we cannot exclude the potential contribution of vaccination-induced inflammatory responses to the upregulation of Nanog.
Nanog inhibition represents an important strategy for the control of tumor growth since we found that in vivo knockdown of siNanog led to tumor growth retardation. This could be attributed to the repression of the CSCs considered to be essential for tumor maintenance in many solid malignancies, including cervical cancer (31) . It has also been documented that elimination of CSCs can potentiate the effects of chemotherapy or radiotherapy (32- 
